PA
BNTX icon

Probity Advisors’s BioNTech BNTX Stock Holding History

Probity Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Buy
3,360
+129
+4% +$12.1K 0.04% 199
2026
Q1 		$287K Buy
3,231
+368
+13% +$37.8K 0.05% 206
2025
Q4 		$273K Buy
2,863
+357
+14% +$36K 0.04% 210
2025
Q3 		$247K Buy
2,506
+135
+6% +$14.4K 0.04% 218
2025
Q2 		$252K Buy
+2,371
New +$239K 0.04% 207
2025
Q1 		– Sell
-1,970
Closed -$224K – 230
2024
Q4 		$224K Buy
1,970
+154
+8% +$17.6K 0.04% 216
2024
Q3 		$216K Buy
+1,816
New +$167K 0.04% 218

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Probity Advisors's BNTX Position: Q2 2026 in Review

Probity Advisors increased its BioNTech (BNTX) stake by 4% in Q2 2026, buying an estimated $12.1K and bringing the position to 3,360 shares worth $313K. The position accounts for 0.04% of the portfolio, ranked #199.

Probity Advisors first reported a position in BNTX in Q3 2024 and has held it in 7 quarters since. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Probity Advisors held 3,360 shares of BioNTech worth $313K as of Q2 2026.
  • Probity Advisors bought 129 BioNTech shares in Q2 2026, an estimated $12.1K.
  • BioNTech made up 0.04% of Probity Advisors's portfolio in Q2 2026, its #199 holding.
  • Probity Advisors first reported a position in BioNTech in Q3 2024 and has held it in 7 quarters since.
  • 283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Probity Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.